EGFR and non-small cell lung carcinoma: Given the encouraging findings of the U31402-A-U102 investigation, the HERTHENA-Lung program was initiated to more thoroughly assess the safety and effectiveness of patritumab deruxtecan in patients bearing EGFR-mutated NSCLC.